Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug

Drug Metabolism and Disposition

Volumn 36, Issue 6, 2008, Pages 1016-1029

  Bauman, Jonathan N ^a   Frederick, Kosea S ^a   Sawant, Aarti ^a   Walsky, Robert L ^a   Cox, Loretta M ^a   Obach, Ronald S ^a   Kalgutkar, Amit S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBON; CYANIDE; CYTOCHROME P450 3A4; GLUTATHIONE; NEFAZODONE; PIPERAZINE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THIOL;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN TISSUE; HYDROXYLATION; LIVER MICROSOME; LIVER TOXICITY; OXIDATION; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; CYANIDES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; PIPERAZINES; QUINOLONES; TRIAZOLES;

EID: 44149108220     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.020545     Document Type: Article

References (25)

1. Andrade RJ and Lucena MI (2003) Drug-induced hepatotoxicity. N Engl J Med 349:1974-1976.
2. Argoti D, Liang L, Conteh A, Chen L, Berhas D, Yu C-P, Vouros P, and Yang E (2005) Cyanide trapping of iminium ion reactive intermediates followed by detection and structure identification using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Chem Res Toxicol 18:1537-1544.
3. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325.
4. Barbhaiya RH, Dandekar KA, and Greene DS (1996) Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans. Drug Metab Dispos 24:91-95.
5. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, and Greenblatt DJ (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
6. Caccia S (2007) N-Dealkylation of arylpiprazine derivatives: Disposition and metabolism of the 1-arylpiperazines formed. Curr Drug Metab 8:612-622.
7. Choi S (2003) Nefazodone (serzone) withdrawn because of hepatotoxicity. CMAJ 169:1187.
8. Evans DC, Watt AP, Nicoll-Griffith DA, and Baillie TA (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3-16.
9. García-Pando AC, García del Pozo J, Sánchez AS, Martín AV, Rueda de Castro AM, and Lucena MI (2002) Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63:135-137.
10. Greene DS and Barbhaiya RH (1997) Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 33:260-275.
11. Hinson JA (1983) Reactive metabolites of phenacetin and acetaminophen: a review. Environ Health Perspect 49:71-79.
12. Kalgutkar AS and Soglia JR (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opin Drug Metab Toxicol 1:91-142.
13. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, Henne KR, Mutlib AE, Dalvie DK, Lee JS, Nakai Y, et al.(2005a) A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225.
14. Kalgutkar AS, Vaz AD, Lame ME, Henne KR, Soglia J, Zhao SX, Abramov YA, Lombardo F, Collin C, Hendsch ZS, et al. (2005b) Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab Dispos 33:243-253.
15. Kitani M, Miyamoto G, Nagasawa M, Yamada T, Matsubara J, Uchida M, and Odomi M (1997) Biotransformation of the novel inotropic agent toborinone (OPC-18790) in rats and dogs. Evidence for the formation of novel glutathione and two cysteine conjugates. Drug Metab Dispos 25:663-674.
16. Li AC, Shou WZ, Mai TT, and Jiang XY (2007) Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms. Rapid Commun Mass Spectrom 21:4001-4008.
17. Mallikaarjun S, Salazar DE, and Bramer SL (2004) Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 44:179-187.
18. Mayol RF, Cole CA, Luke GM, Colson KL, and Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 22:304-311.
19. Molden E, Lunde H, Lunder N, and Refsum H (2006) Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 28:744-749.
20. Nelson SD (2001) Structure toxicity relationships-how useful are they in predicting toxicities of new drugs? Adv Exp Med Biol 500:33-43.
21. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255.
22. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, and Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177-202.
23. Peterman SM, Duczak N Jr., Kalgutkar AS, Lame ME, and Soglia JR (2006) Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements. J Am Soc Mass Spectrom 17:363-375.
24. Stewart DE (2002) Hepatic adverse reactions with nefazodone. Can J Psychiatry 47:375-377.
25. Zheng J, Ma L, Xin B, Olah T, Griffith Humphreys W, and Zhu M (2007) Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry. Chem Res Toxicol 20:757-766.